APA citiranje

Jain, L., Chain, A. S., Tatosian, D. A., Hing, J., Passarell, J. A., Kauh, E. A., & Lai, E. (2019). Pharmacokinetic–pharmacodynamic (dipeptidyl peptidase‐4 inhibition) model to support dose rationale in diabetes patients, including those with renal impairment, for once‐weekly administered omarigliptin. Br J Clin Pharmacol.

Citação norma Chicago

Jain, Lokesh, Anne S.Y Chain, Daniel A. Tatosian, Jeremy Hing, Julie A. Passarell, Eunkyung A. Kauh, and Eseng Lai. "Pharmacokinetic–pharmacodynamic (dipeptidyl Peptidase‐4 Inhibition) Model to Support Dose Rationale in Diabetes Patients, Including Those With Renal Impairment, for Once‐weekly Administered Omarigliptin." Br J Clin Pharmacol 2019.

MLA citiranje

Jain, Lokesh, et al. "Pharmacokinetic–pharmacodynamic (dipeptidyl Peptidase‐4 Inhibition) Model to Support Dose Rationale in Diabetes Patients, Including Those With Renal Impairment, for Once‐weekly Administered Omarigliptin." Br J Clin Pharmacol 2019.